Your SlideShare is downloading. ×
UBS Global Life Sciences Conference
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

UBS Global Life Sciences Conference

918
views

Published on

Thursday, September 20, 2012 …

Thursday, September 20, 2012
9:00 AM E.D.T.


0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
918
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
13
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. UBS 2012 Global HealthcareConferencePfizer WorldwideResearch & DevelopmentMikael Dolsten, M.D., Ph.D. September 20, 2012
  • 2. Forward-Looking Statements• Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2011 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.• Also, the discussions will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer’s Current Reports on Form 8-K dated July 31, 2012 and August 13, 2012.These reports are available on our website at www.pfizer.comin the "Investors—SEC Filings" section. 2
  • 3. Pfizer R&D Strategy ― 3 Major Priorities Delivering the Innovating New R&D Ecosystem Portfolio Capabilities of the Future Sharpening focus in areas Investing in the Highly networked R&D with greatest scientific & technologies to enable & superior outcomes in commercial ROI tomorrow’s products Precision patient subsets • 8 Key Approvals • Antibody Drug • Centers for Therapeutic Conjugates Innovation (CTI) (2011 – 2012 YTD) • Therapeutic Vaccines • Xalkori • Eliquis and tofacitinib in Registration • Sophisticated NCE Design 3
  • 4. Improving R&D Return on InvestmentUnlocking Additional Value for Shareholders Three Key Principles 1 2 3 Greater Strategic Differentiated Focus Externalization Innovation Quality Probability Speed Cost of Output of Success • Termination of numerous non-core research projects • Neusentis (Pain) unit launched in Cambridge, UK • New portfolio prioritization & governance • CVMED & Neuroscience units moved to Cambridge, MA accountability • Acquired Icagen to expand Ion Channel research IP • Earlier integration of science, business & finance • Agreement with Mylan to acquire our A&R portfolio • Expanded Centers for Therapeutic Innovation • Acquired Excaliard Pharmaceuticals (CTI); agreements with 21 leading AMCs • Initiated Precision Medicine research collaboration • Transition from 17 functional service providers to 2 with Medco/Express Scripts strategic partners for clinical trials (ICON & Parexel) 4
  • 5. Today’s Key Late Stage Assets Key Post-POC Programs Key Products In Registration Eliquis™ (apixaban) Eliquis™ (apixiban) Venous Thromboembolism Treatment Stroke Prevention in AFib; US/EU/Japan Inlyta™ Tofacitinib First Line Renal Cell Carcinoma Rheumatoid Arthritis; US/EU/Japan Tofacitinib Tafamidis meglumine Psoriasis and Ulcerative Colitis Transthyretin amyloidosis polyneuropathy; US Dacomitinib (approved in EU) Non-Small Cell Lung Cancer Bosulif™ (bosutinib) Chronic Myelogenous Leukemia; EU Inotuzumab Ozogamicin (approved in US) Aggressive Non-Hodgkins Lymphoma and Acute Lymphoblastic Leukemia Remoxy™/ Embeda®* Pain; US Meningococcal B Adolescent Vaccine Prevention of Meningococcal Infection in Adolescents Xalkori® (crizotinib) ALK-positive Advanced NSCLC; EU PD-332991 (CDK 4/6) (approved in US and Japan) Advanced ER+HER2- Breast Cancer Bazedoxifene – conjugated estrogens *Planning re-submission of Embeda to relevant regulatory authorities Menopausal vasomotor symptoms, EU 5
  • 6. Precision Medicine R&D Shaping a Differentiated Pipeline Right Drug Right Target Right Patient (or Combinations) Selective design and Genetic validation; Rare Phenotyping and delivery; combinations phenotypes Genotyping for complex diseases PCSK9 Inotuzumab Nav family (targeted inhibition) PI3K/mTOR + Estrogen Inhibitors (in genetically-predisposed patients) PD-332991 (CDK 4/6) 6
  • 7. Coupled with Leading Technology PlatformsAcross Modalities Pfizer leads in cutting-edge …And is building technology platforms….. technologies of the future Vaccines Inflammation & Tissue-Specific Immunology NCEs CovX Bodies Peptides ADCs Oncology Neuroscience Targeted Antibody Mixtures IgG Heterodimers Vaccines NCEs Cardiovascular & Metabolic Disease Combinatorial Biologics Pain & Sensory Therapeutic DisordersAntibodies Proteins Biosimilars Long Lasting IgG Nexgen ADCs Rare Disease 7
  • 8. Next Wave Pipeline Shapes the Future Immunology & Inflammation Beyond RA: Transforming Chronic Disease IL6, MAdCAM P38, IL7R 8
  • 9. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Inflammation Metabolic Diseases Beyond RA: New Paths to Transforming Chronic Sustained Leadership Disease IL6, MAdCAM PCSK9, Gka P38, IL7R PDE5, FGF21 9
  • 10. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO 10
  • 11. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Platform for all Ages and Geographies Staph, Nicotine C. diff, IgE 11
  • 12. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience & Pain Platform for all Ages Unlocking Circuitry and Geographies & Genetics Staph, Nicotine PDEs, Nav family C. diff, IgE 5HT6, AMPA 12
  • 13. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience Biosimilars & Rare & Pain Diseases Platform for all Ages Unlocking Circuitry High-Value and Geographies & Genetics Specialized Markets Staph, Nicotine PDEs, Nav family Factor 7, rituximab C. diff, IgE 5HT6, AMPA trastuzumab, GDF8 13
  • 14. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience Biosimilars & Rare & Pain Diseases Platform for all Ages Unlocking Circuitry High-Value and Geographies & Genetics Specialized Markets Staph, Nicotine PDEs, Nav family Factor 7, rituximab C. diff, IgE 5HT6, AMPA trastuzumab, GDF8 14
  • 15. THANK YOU